PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) is a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D process and commercial production. Its core businesses include a rationally designed building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial.
PharmaBlock (USA), Inc.,located in the Greater Philadelphia Area, is a subsidiary of PharmaBlock Sciences (Nanjing), Inc., The company opened its first US facility in the Bay Area of California in 2012 and established US headquarters in Pennsylvania in 2017. With an experienced chemistry team and state-of-the-art equipment, PharmaBlock (USA) is providing a large collection of high-quality and novel building blocks, timely customer service, and process R&D services using new technologies such as flow chemistry and micropacked bed hydrogenation to bring greener, safer, innovative, and cost-efficient solutions to pharmaceutical industry.
PharmaBlock has partnered with most of the top 20 pharmaceutical companies and hundreds of small to medium-sized biotech companies worldwide. In addition to the US facilities, PharmaBlock has three main facilities in China. Its global headquarters is located in Nanjing, Jiangsu Province, China, with 679,000 ft2 lab space focusing on the design, synthesis, and supply of lab-scale building blocks, and process R&D of key intermediates and APls. It has two manufacturing sites located in Zhejiang and Shandong Provinces in China, with around 250 m3 combined reactor volume, ranging from 200 L to 6,300 L of reactor size.